Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Inger Helen Olesen
Observed names:
I. Olesen,
Inger H. Olesen,
Inger Olesen
Institution:
Barwon Health
Observed institutions:
The University of Sydney,
Barwon Health,
Deakin University,
Walter and Eliza Hall Institute of Medical Research,
Geelong Hospital,
Royal North Shore Hospital
show all 6
OpenAlex ID:
A5010940695
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
2020
·
Jacobus Pfisterer
, Catherine M Shannon
, et al.
·
The Lancet Oncology
·
166
PDF
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2021
·
Ksenija Nesic
, Olga Kondrashova
, et al.
·
Cancer Research
·
90
PDF
The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer
2016
·
Shreya Tocaciu
, Lesley J. Oliver
, et al.
·
Integrative Cancer Therapies
·
71
PDF
Predictors of the accuracy of self‐reported height and weight in adolescent female school students
2004
·
Suzanne Abraham
, Georgina Luscombe
, et al.
·
International Journal of Eating Disorders
·
47
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
2024
·
Ksenija Nesic
, John J. Krais
, et al.
·
Molecular Cancer
·
36
PDF
Targeting homologous recombination deficiency in uterine leiomyosarcoma
2023
·
Genevieve Dall
, Cassandra J. Vandenberg
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
22
PDF
Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer
2013
·
Janette Vardy
, Haryana M Dhillon
, et al.
·
SpringerPlus
·
21
PDF
Characteristics of cancer diagnoses and staging in South Western Victoria: A rural perspective
2014
·
Patricia Banks
, Leigh M. Matheson
, et al.
·
Australian Journal of Rural Health
·
10
Impacts of a Clinical Quality Registry on Lung Cancer Quality Measures: A Retrospective Observational Study of the Victorian Lung Cancer Registry
2025
·
R.G. Stirling
, U. Samankula
, et al.
·
Clinical Oncology
·
9
Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one
2018
·
Gregory M. Peterson
, Jackson Thomas
, et al.
·
Journal of Clinical Pharmacy and Therapeutics
·
9
PDF
Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator
2024
·
Sanuki Tissera
, Baki Billah
, et al.
·
Clinical Lung Cancer
·
8
Patterns of care for people with small cell lung cancer in Victoria, 2011–19: a retrospective, population‐based registry data study
2023
·
Joanna Huang
, Wasek Faisal
, et al.
·
The Medical Journal of Australia
·
6
PDF
Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer.
2014
·
Mustafa Khasraw
, Linda West
, et al.
·
Journal of Clinical Oncology
·
2
Impact of Stage‐Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia
2025
·
Sanuki Tissera
, Baki Billah
, et al.
·
Thoracic Cancer
·
1
PDF
Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).
2015
·
Mustafa Khasraw
, Violet Rudo Mukaro
, et al.
·
Journal of Clinical Oncology
·
1
Tailored Neoadjuvant Epirubicin and Cyclophosphamide and Nanoparticle Albumin Bound (nab) Paclitaxel for Newly Diagnosed Breast Cancer
2013
·
Mustafa Khasraw
, Lindsay West
, et al.
·
Figshare
·
1
Uneven Ground: Survival Differences Among Victorian Lung Cancer Patients by Location of Residence (2011–2023): A Retrospective Cohort Study
2026
·
Evangeline Samuel
, Eldho Paul
, et al.
·
The Medical Journal of Australia
Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study
2026
·
Alison Hiong
, Julien Robinson
, et al.
·
JTO Clinical and Research Reports
Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry
2026
·
Rob G. Stirling
, Sanuki Tissera
, et al.
·
JTO Clinical and Research Reports
PT2.17.02 Impact of Timely Treatment Initiation on Outcomes in Non-Small Cell Lung Cancer. A Registry Based Observational Study
2025
·
J. Robinson
, A. Hiong
, et al.
·
Journal of Thoracic Oncology
P1.17.18 Victorian Lung Cancer Registry Impacts on Multi-Disciplinary Lung Cancer Meeting Presentation
2025
·
L. Irving
, J. Zeng
, et al.
·
Journal of Thoracic Oncology
Data from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2023
·
Ksenija Nesic
, Olga Kondrashova
, et al.
Supplementary Methods from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2023
·
Ksenija Nesic
, Olga Kondrashova
, et al.
Supplementary Methods from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2023
·
Ksenija Nesic
, Olga Kondrashova
, et al.
Supplementary Figures from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2023
·
Ksenija Nesic
, Olga Kondrashova
, et al.
Show more works
View as search
Works count:
33
Citation count:
500
H-index:
9
I10-index:
8
Year
Topic
Type
